Lesson plan
MK-0773
MK-0773, also known as PF-05314882, is a steroidal, orally active selective androgen receptor modulator (SARM) that was under development by Merck and GTx for the treatment of sarcopenia (loss of muscle mass) in women and men. Clinical trials for sarcopenia began in late 2007 but the collaboration between Merck and GTx ended in early 2010 and GTx terminated development of MK-0773 shortly thereafter. MK-0773 was developed as a more advanced version of the related compound TFM-4AS-1. MK-0773 is a 4-azasteroid and a potent and selective agonist of the androgen receptor (AR). It binds to the AR with an EC 50 of 6.6 nM and is a partial agonist in transactivation modulation of the AR with an IP of 25 nM and E max of 78% and has a TRAF2 E max of 29% and an N/C interaction (virilization-related) counterscreen assay E max of 2%. That is, it produces promoter activation but induces the N/C interaction almost negligibly. MK-0773 is reportedly four times as potent as testosterone as an agonist of the AR. The drug is selective and does not bind to other steroid hormone receptors such as the progesterone receptor or glucocorticoid receptor and shows no significant inhibition of 5α-reductase (IC 50 > 10 μM). In addition, it is non-aromatizable and hence has no potential for estrogenic effects or side effects, like gynecomastia.…
Article summary
MK-0773, also known as PF-05314882, is a steroidal, orally active selective androgen receptor modulator (SARM) that was under development by Merck and GTx for the treatment of sarcopenia (loss of muscle mass) in women and men. Clinical trials for sarcopenia began in late 2007 but the collaboration between Merck and GTx ended in early 2010 and GTx terminated development of MK-0773 shortly thereafter. MK-0773 was developed as a more advanced version of the related compound TFM-4AS-1. MK-0773 is a 4-azasteroid and a potent and selective agonist of the androgen receptor (AR). It binds to the AR with an EC 50 of 6.6 nM and is a partial agonist in transactivation modulation of the AR with an IP of 25 nM and E max of 78% and has a TRAF2 E max of 29% and an N/C interaction (virilization-related) counterscreen assay E max of 2%. That is, it produces promoter activation but induces the N/C interaction almost negligibly. MK-0773 is reportedly four times as potent as testosterone as an agonist of the AR. The drug is selective and does not bind to other steroid hormone receptors such as the progesterone receptor or glucocorticoid receptor and shows no significant inhibition of 5α-reductase (IC 50 > 10 μM). In addition, it is non-aromatizable and hence has no potential for estrogenic effects or side effects, like gynecomastia.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.